Fig. 2From: Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE studyLong-term effect of benralizumab on lung function. FEV1 (A, C) and FVC (B, D) values pre- and post-BD are shown at various time points (index date and 4, 16, 24, 48, 96 weeks of treatment with benralizumab)Back to article page